# Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative

> **NCT04209140** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 320 (estimated)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** lithium treatment

## Key facts

- **NCT ID:** NCT04209140
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-10
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209140, "Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04209140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*